Overcoming cell therapy manufacturing bottlenecks
C-Stem™ is a biomimetic cell culture platform allowing for the mass-production of stem cell- derived therapies with unprecedented cell quality.
Scale-up
C-Stem™ generates scale-independent cell culture micro-environments, allowing to progress to larger bioreactors without changing key parameters.
Safety
C-Stem™ perserves genomic integrity and yields mature cell phenotypes, thereby enhancing the safety of cellular products
Efficacy
C-Stem™ delivers functional microtissues, which were shown to improve graft integration and reduce time-to-effect.
Previous
Next
Step-by-step
The C-Stem™ process
#1 industrial-grade microfluidics
High-throughput stem cell encapsulation
- GMP encapsulation device
- Automated, closed, single-use
- Throughput: > 1,000 capsules per second
#2 biomimetic 3D micro-environments
Self-organization in in vivo-like stem cell microtissues
- Epiblast structure promotes fast & high-fidelity cell division
- Capsule lets nutrients, gas and growth factors in & out
- Capsule protects cellular content from mechanical stress
#3 Bioreactor scale-up
Exponential stem cell expansion & differentiation in bioreactors
- >100-fold hPSC amplification per week
- Best-in-class cell viability, pluripotency & genomic integrity
- Single-batches of over 10 billion cells in 10L bioreactor
- Differentiation into functional microtissues in bioreactor
Previous
Next
#4 EASY downstream processing & delivery
Functional 3D microtissues ready for transplantation
- Capsule removal in minutes to release cell content
- Mature cell phenotypes enhance product safety & efficacy
- 3D microtissue format facilitates handling & delivery
PARTNERSHIP MODEL
Our job: to bring the benefits of C-Stem™ as fast as possible to patients through in-house programs and strategic alliances.
Adapt 2D to 3D
Our 3D stem cell biology team dedicated R&D platform can adapt existing protocols to C-Stem™ for optimal hPSC amplification and differentiation
Scale-up early
Our bioproduction team can develop bioreactor-based manufacturing processes to secure commercial-scale batches for non-clinical and early clinical phases
Enhance delivery
Our scientists can provide expertise in logistics, delivery formats and medical devices to maximize the clinical convenience and therapeutic benefits of the product
Optimize manufacturing
Our encapsulation and analytical development teams can provide continuous support for the optimization of manufacturing processes
Partner with us
Contact our team !
C-Stem™ technology: Scaling-up iPS-derived cell therapy manufacturing in bioreactors
TreeFrog Therapeutics has developed C-Stem, a technology allowing for the mass-production of iPS-derived cell therapies in large-scale bioreactors. C-stem is based on a proprietary high-throughput cell encapsulation technology which generates over 1,000 capsules per second. Each stem cell capsule constitutes a biomimetic micro-environment which recapitulates an in-vivo like stem cell niche. In the capsule, pluripotent stem cells self-organize to form an epiblast-like 3D stem cell microtissue which promotes exponential pluripotent stem cell growth, maintenance of homogenous pluripotency and high-fidelity chromosome segregation (preservation of genomic integrity). But the capsule is also protecting stem cells during manufacturing proceses. In fact, C-Stem allows for the scale-independent exponential amplification of hiPSCs and their differentiation into functional 3D microtissues in industrial bioreactors.